Boehringer Ingelheim and IBM team up to make antibodies with generative AI

Boehringer In­gel­heim is the lat­est drug­mak­er turn­ing to gen­er­a­tive AI for help in mak­ing med­i­cines. On Tues­day, the Ger­man phar­ma gi­ant an­nounced a part­ner­ship with IBM to cre­ate an­ti­bod­ies us­ing the com­put­er com­pa­ny’s ar­ti­fi­cial in­tel­li­gence tech­nol­o­gy.

The com­pa­nies, each among the old­est in their re­spec­tive in­dus­tries, are not mere­ly jump­ing aboard the lat­est trend. Boehringer told End­points News that the part­ner­ship was years in the mak­ing. It sees us­ing AI for drug de­sign as a long-term in­vest­ment, and not nec­es­sar­i­ly one that will flood its pipeline with drugs any­time soon.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.